Safety of hydroxychloroquine for treatment or prevention of SARS ‐CoV‐2 infection: A rapid systematic review and meta‐analysis of randomized clinical trials
ConclusionSafety profile of HCQ appears to be unsatisfactory when used to treat or prevent COVID ‐19, especially in the light of unproved clinical benefit.
Source: Immunity, Inflammation and Disease - Category: Allergy & Immunology Authors: Alberto Enrico Maraolo,
Adriano Grossi Tags: REVIEW Source Type: research
More News: Allergy & Immunology | Clinical Trials | Coronavirus | COVID-19 | Hydroxychloroquine | Pandemics | SARS | Study